Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.

Tao, Hong; Liu, Zhe; Mu, Jing; Gai, Fei; Huang, Zhan; Shi, Liang

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.

Tao, Hong; Liu, Zhe; Mu, Jing; Gai, Fei; Huang, Zhan; Shi, Liang.

Afiliación

Tao H; Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Liu Z; Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Mu J; Department of Pathology, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Thoracic Tumor Research Institute, Beijing Tuberculosis, Beijing, China.
Gai F; Department of Medical Business, Amoy Diagnostics Co., Ltd, Xiamen, China.
Huang Z; Department of Medical Business, Amoy Diagnostics Co., Ltd, Xiamen, China.
Shi L; Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China. shiliang@bjmu.edu.cn.

Diagn Pathol ; 17(1): 27, 2022 Feb 10.

Article en En | MEDLINE | ID: mdl-35144623

Asunto(s)

Adenocarcinoma del Pulmón; Neoplasias Pulmonares; Fosfoproteínas Fosfatasas/genética; Adenocarcinoma del Pulmón/tratamiento farmacológico; Adenocarcinoma del Pulmón/genética; Adenocarcinoma del Pulmón/patología; Adulto; Quinasa de Linfoma Anaplásico/genética; Crizotinib/uso terapéutico; Femenino; Humanos; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/patología; Persona de Mediana Edad; Proteínas de Fusión Oncogénica/genética; Inhibidores de Proteínas Quinasas/uso terapéutico; Factores de Transcripción/genética

Palabras clave

ALK-SSH2; ARID2-ALK; Anaplastic lymphoma kinase fusion; Lung adenocarcinoma; Targeted therapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fosfoproteínas Fosfatasas / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Diagn Pathol Asunto de la revista: PATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google